Mar 02, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 2, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented results from Cohort 3 and initial twice daily (BID) dosing safety and efficacy data for poziotinib from Cohort 5
|
|
Feb 26, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 26, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS ® (eflapegrastim) in patients
|
|
Feb 23, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 23, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted
|
|
Feb 04, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day.
|
|
Jan 22, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of
|
|
Jan 05, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at
|
|
Dec 22, 2020
|
FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients with EGFR exon 20
|
|
Dec 14, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 14, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms.
|
|
Dec 04, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 4, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at the upcoming San Antonio
|
|
Nov 09, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 9, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
|
|
Nov 04, 2020
|
FDA deferred action on the BLA for ROLONTIS ® (eflapegrastim) due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 insertion mutations in previously treated
|
|
Oct 28, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 28, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate
|
|
Oct 26, 2020
|
Agency cites inability to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel restrictions HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 26, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology
|
|
Sep 18, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously
|
|
Sep 14, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 14, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in
|
|
Sep 08, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 8, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
|
|
Aug 10, 2020
|
Recently announced positive topline results in HER2 exon 20 insertion mutations from Cohort 2 of the poziotinib ZENITH20 trial Company is in process of requesting a pre-NDA meeting with the FDA seeking an indication for second-line NSCLC patients with HER2 exon 20 insertion mutations BLA for
|
|
Aug 05, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 5, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the underwriters of its previously announced public offering of common
|
|
Aug 03, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 3, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate
|
|
Jul 30, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 30, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the pricing of an underwritten public offering of 21,666,667 shares of its
|
|